{"id":54419,"date":"2026-01-16T20:19:25","date_gmt":"2026-01-16T12:19:25","guid":{"rendered":"https:\/\/flcube.com\/?p=54419"},"modified":"2026-01-16T20:19:26","modified_gmt":"2026-01-16T12:19:26","slug":"boston-scientific-to-acquire-penumbra-in-14-5-billion-deal-bolsters-thrombectomy-leadership","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=54419","title":{"rendered":"Boston Scientific to Acquire Penumbra in $14.5\u202fBillion Deal, Bolsters Thrombectomy Leadership"},"content":{"rendered":"\n<p><strong>Boston Scientific Corporation<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/BSX:NYSE\">NYSE:\u202fBSX<\/a>) and <strong>Penumbra, Inc.<\/strong> (<a href=\"https:\/\/www.google.com\/finance\/quote\/PEN:NYSE\">NYSE:\u202fPEN<\/a>) announced a definitive agreement for Boston Scientific to acquire Penumbra in a <strong>cash and stock transaction valuing the company at USD\u202f374 per share<\/strong>, reflecting an enterprise value of approximately <strong>USD\u202f14.5\u202fbillion<\/strong>. The transaction is expected to close in <strong>2026<\/strong>, subject to Penumbra stockholder approval and customary closing conditions.<\/p>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-transaction-overview\">Transaction Overview<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td><strong>Acquirer<\/strong><\/td><td>Boston Scientific Corporation (NYSE:\u202fBSX)<\/td><\/tr><tr><td><strong>Target<\/strong><\/td><td>Penumbra, Inc. (NYSE:\u202fPEN)<\/td><\/tr><tr><td><strong>Purchase Price<\/strong><\/td><td>USD\u202f374 per share<\/td><\/tr><tr><td><strong>Enterprise Value<\/strong><\/td><td>USD\u202f14.5\u202fbillion<\/td><\/tr><tr><td>**Payment Structure<\/td><td>Cash and stock<\/td><\/tr><tr><td><strong>Expected Close<\/strong><\/td><td>2026<\/td><\/tr><tr><td>**Approval Requirements<\/td><td>Penumbra stockholder approval, regulatory clearances<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-target-profile-penumbra\">Target Profile: Penumbra<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Attribute<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>**Business Focus<\/td><td>World-leading thrombectomy company<\/td><\/tr><tr><td>**Key Products<\/td><td>Lightning Bolt, Lightning Flash (CAVT systems) for blood clot removal; minimally invasive peripheral embolization system<\/td><\/tr><tr><td>**Indications<\/td><td>Ischemic stroke, pulmonary embolism, acute limb ischemia<\/td><\/tr><tr><td>**2025 Revenue<\/td><td>USD\u202f1.4\u202fbillion<\/td><\/tr><tr><td>**Key Advantages<\/td><td>Speed, safety, simplicity in head-to-toe clot removal<\/td><\/tr><tr><td>**Market Position<\/td><td>#1 in computer-assisted vacuum thrombectomy (CAVT) technology<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-strategic-rationale-amp-market-context\">Strategic Rationale &amp; Market Context<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Market Size:<\/strong> Global thrombectomy market valued at <strong>$3.2\u202fbillion<\/strong> (2026E), growing at <strong>9.5\u202f% CAGR<\/strong><\/li>\n\n\n\n<li><strong>Competitive Landscape:<\/strong> Acquisition positions Boston Scientific against <strong>Stryker (Navien)<\/strong>, <strong>Medtronic (Solitaire)<\/strong>, and <strong>Terumo<\/strong><\/li>\n\n\n\n<li><strong>Synergies:<\/strong> Combines Penumbra\u2019s <strong>thrombectomy leadership<\/strong> with Boston Scientific\u2019s <strong>vascular and peripheral intervention portfolio<\/strong>, creating a <strong>comprehensive stroke and PE treatment platform<\/strong><\/li>\n\n\n\n<li><strong>Revenue Accretion:<\/strong> Expected to be <strong>accretive to BSX adjusted EPS<\/strong> by 2027<\/li>\n<\/ul>\n\n\n\n<h2 class=\"wp-block-heading\" id=\"h-financial-implications\">Financial Implications<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Parameter<\/th><th>2026E<\/th><th>2027E<\/th><th>2028E<\/th><\/tr><\/thead><tbody><tr><td>**Combined Thrombectomy Revenue<\/td><td>$1.8\u202fbillion<\/td><td>$2.1\u202fbillion<\/td><td>$2.5\u202fbillion<\/td><\/tr><tr><td>**Market Share (Post\u2011Acquisition)<\/td><td>35\u202f%<\/td><td>38\u202f%<\/td><td>42\u202f%<\/td><\/tr><tr><td>**Cost Synergies<\/td><td>\u2013<\/td><td>$150\u202fmillion<\/td><td>$200\u202fmillion<\/td><\/tr><tr><td>**Integration Costs<\/td><td>$75\u202fmillion<\/td><td>$50\u202fmillion<\/td><td>\u2013<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<p><strong>Forward\u2011Looking Statements<\/strong><br>This brief contains forward\u2011looking statements regarding transaction completion, revenue synergies, and market consolidation. Actual results may differ due to regulatory delays, integration challenges, and competitive responses.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Boston Scientific Corporation (NYSE:\u202fBSX) and Penumbra, Inc. (NYSE:\u202fPEN) announced a definitive agreement for Boston Scientific&#8230;<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2}},"categories":[7,10],"tags":[315,20,1160,4561,4560],"class_list":["post-54419","post","type-post","status-publish","format-standard","hentry","category-company","category-deals","tag-boston-scientific","tag-finance","tag-nyse-bsx","tag-nyse-pen","tag-penumbra"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v23.6 (Yoast SEO v27.5) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>Boston Scientific to Acquire Penumbra in $14.5\u202fBillion Deal, Bolsters Thrombectomy Leadership - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Boston Scientific Corporation (NYSE:\u202fBSX) and Penumbra, Inc. (NYSE:\u202fPEN) announced a definitive agreement for Boston Scientific to acquire Penumbra in a cash and stock transaction valuing the company at USD\u202f374 per share, reflecting an enterprise value of approximately USD\u202f14.5\u202fbillion. The transaction is expected to close in 2026, subject to Penumbra stockholder approval and customary closing conditions.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=54419\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Boston Scientific to Acquire Penumbra in $14.5\u202fBillion Deal, Bolsters Thrombectomy Leadership\" \/>\n<meta property=\"og:description\" content=\"Boston Scientific Corporation (NYSE:\u202fBSX) and Penumbra, Inc. (NYSE:\u202fPEN) announced a definitive agreement for Boston Scientific to acquire Penumbra in a cash and stock transaction valuing the company at USD\u202f374 per share, reflecting an enterprise value of approximately USD\u202f14.5\u202fbillion. The transaction is expected to close in 2026, subject to Penumbra stockholder approval and customary closing conditions.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=54419\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-01-16T12:19:25+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-01-16T12:19:26+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"2560\" \/>\n\t<meta property=\"og:image:height\" content=\"1894\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54419#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54419\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"Boston Scientific to Acquire Penumbra in $14.5\u202fBillion Deal, Bolsters Thrombectomy Leadership\",\"datePublished\":\"2026-01-16T12:19:25+00:00\",\"dateModified\":\"2026-01-16T12:19:26+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54419\"},\"wordCount\":283,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"keywords\":[\"Boston Scientific\",\"Finance\",\"NYSE: BSX\",\"NYSE:\u202fPEN\",\"Penumbra\"],\"articleSection\":[\"Company\",\"Deals\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54419#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54419\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=54419\",\"name\":\"Boston Scientific to Acquire Penumbra in $14.5\u202fBillion Deal, Bolsters Thrombectomy Leadership - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"datePublished\":\"2026-01-16T12:19:25+00:00\",\"dateModified\":\"2026-01-16T12:19:26+00:00\",\"description\":\"Boston Scientific Corporation (NYSE:\u202fBSX) and Penumbra, Inc. (NYSE:\u202fPEN) announced a definitive agreement for Boston Scientific to acquire Penumbra in a cash and stock transaction valuing the company at USD\u202f374 per share, reflecting an enterprise value of approximately USD\u202f14.5\u202fbillion. The transaction is expected to close in 2026, subject to Penumbra stockholder approval and customary closing conditions.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54419#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=54419\"]}]},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=54419#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Boston Scientific to Acquire Penumbra in $14.5\u202fBillion Deal, Bolsters Thrombectomy Leadership\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"Boston Scientific to Acquire Penumbra in $14.5\u202fBillion Deal, Bolsters Thrombectomy Leadership - Insight, China&#039;s Pharmaceutical Industry","description":"Boston Scientific Corporation (NYSE:\u202fBSX) and Penumbra, Inc. (NYSE:\u202fPEN) announced a definitive agreement for Boston Scientific to acquire Penumbra in a cash and stock transaction valuing the company at USD\u202f374 per share, reflecting an enterprise value of approximately USD\u202f14.5\u202fbillion. The transaction is expected to close in 2026, subject to Penumbra stockholder approval and customary closing conditions.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=54419","og_locale":"en_US","og_type":"article","og_title":"Boston Scientific to Acquire Penumbra in $14.5\u202fBillion Deal, Bolsters Thrombectomy Leadership","og_description":"Boston Scientific Corporation (NYSE:\u202fBSX) and Penumbra, Inc. (NYSE:\u202fPEN) announced a definitive agreement for Boston Scientific to acquire Penumbra in a cash and stock transaction valuing the company at USD\u202f374 per share, reflecting an enterprise value of approximately USD\u202f14.5\u202fbillion. The transaction is expected to close in 2026, subject to Penumbra stockholder approval and customary closing conditions.","og_url":"https:\/\/flcube.com\/?p=54419","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-01-16T12:19:25+00:00","article_modified_time":"2026-01-16T12:19:26+00:00","og_image":[{"width":2560,"height":1894,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","type":"image\/jpeg"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=54419#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=54419"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"Boston Scientific to Acquire Penumbra in $14.5\u202fBillion Deal, Bolsters Thrombectomy Leadership","datePublished":"2026-01-16T12:19:25+00:00","dateModified":"2026-01-16T12:19:26+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=54419"},"wordCount":283,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"keywords":["Boston Scientific","Finance","NYSE: BSX","NYSE:\u202fPEN","Penumbra"],"articleSection":["Company","Deals"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=54419#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=54419","url":"https:\/\/flcube.com\/?p=54419","name":"Boston Scientific to Acquire Penumbra in $14.5\u202fBillion Deal, Bolsters Thrombectomy Leadership - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"datePublished":"2026-01-16T12:19:25+00:00","dateModified":"2026-01-16T12:19:26+00:00","description":"Boston Scientific Corporation (NYSE:\u202fBSX) and Penumbra, Inc. (NYSE:\u202fPEN) announced a definitive agreement for Boston Scientific to acquire Penumbra in a cash and stock transaction valuing the company at USD\u202f374 per share, reflecting an enterprise value of approximately USD\u202f14.5\u202fbillion. The transaction is expected to close in 2026, subject to Penumbra stockholder approval and customary closing conditions.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=54419#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=54419"]}]},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=54419#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"Boston Scientific to Acquire Penumbra in $14.5\u202fBillion Deal, Bolsters Thrombectomy Leadership"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_featured_media_url":"","jetpack_sharing_enabled":true,"_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54419","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=54419"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54419\/revisions"}],"predecessor-version":[{"id":54426,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/54419\/revisions\/54426"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=54419"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=54419"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=54419"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}